Literature DB >> 25082865

Haplo is the new black.

Michael A Pulsipher1.   

Abstract

In this edition of Blood, Bertaina et al report 3-year survival exceeding 90% by using haploidentical αβ+CD3+/CD19+-depleted allogeneic transplantation for children with nonmalignant disorders.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25082865      PMCID： PMC4118482          DOI： 10.1182/blood-2014-06-579714

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

1.  Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation.

Authors:  Katia Perruccio; Antonella Tosti; Emanuela Burchielli; Fabiana Topini; Loredana Ruggeri; Alessandra Carotti; Marusca Capanni; Elena Urbani; Antonella Mancusi; Franco Aversa; Massimo F Martelli; Luigina Romani; Andrea Velardi
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

2.  HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders.

Authors:  Alice Bertaina; Pietro Merli; Sergio Rutella; Daria Pagliara; Maria Ester Bernardo; Riccardo Masetti; Daniela Pende; Michela Falco; Rupert Handgretinger; Francesca Moretta; Barbarella Lucarelli; Letizia P Brescia; Giuseppina Li Pira; Manuela Testi; Caterina Cancrini; Nabil Kabbara; Rita Carsetti; Andrea Finocchi; Alessandro Moretta; Lorenzo Moretta; Franco Locatelli
Journal:  Blood       Date:  2014-05-28       Impact factor: 22.113

3.  Transplantation of anergic histoincompatible bone marrow allografts.

Authors:  E C Guinan; V A Boussiotis; D Neuberg; L L Brennan; N Hirano; L M Nadler; J G Gribben
Journal:  N Engl J Med       Date:  1999-06-03       Impact factor: 91.245

4.  Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.

Authors:  Mauro Di Ianni; Franca Falzetti; Alessandra Carotti; Adelmo Terenzi; Flora Castellino; Elisabetta Bonifacio; Beatrice Del Papa; Tiziana Zei; Roberta Iacucci Ostini; Debora Cecchini; Teresa Aloisi; Katia Perruccio; Loredana Ruggeri; Chiara Balucani; Antonio Pierini; Paolo Sportoletti; Cynthia Aristei; Brunangelo Falini; Yair Reisner; Andrea Velardi; Franco Aversa; Massimo F Martelli
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

5.  Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study.

Authors:  Birgit Federmann; Martin Bornhauser; Christoph Meisner; Lambros Kordelas; Dietrich W Beelen; Gernot Stuhler; Matthias Stelljes; Rainer Schwerdtfeger; Maximilian Christopeit; Gerhard Behre; Christoph Faul; Wichard Vogel; Michael Schumm; Rupert Handgretinger; Lothar Kanz; Wolfgang A Bethge
Journal:  Haematologica       Date:  2012-04-04       Impact factor: 9.941

6.  Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.

Authors:  Marie Bleakley; Shelly Heimfeld; Lori A Jones; Cameron Turtle; Diane Krause; Stanley R Riddell; Warren Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-11       Impact factor: 5.742

7.  Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.

Authors:  Franco Aversa; Adelmo Terenzi; Antonio Tabilio; Franca Falzetti; Alessandra Carotti; Stelvio Ballanti; Rita Felicini; Flavio Falcinelli; Andrea Velardi; Loredana Ruggeri; Teresa Aloisi; Jean Pierre Saab; Antonella Santucci; Katia Perruccio; Maria Paola Martelli; Cristina Mecucci; Yair Reisner; Massimo F Martelli
Journal:  J Clin Oncol       Date:  2005-03-07       Impact factor: 44.544

8.  Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

Authors:  Fabio Ciceri; Chiara Bonini; Maria Teresa Lupo Stanghellini; Attilio Bondanza; Catia Traversari; Monica Salomoni; Lucia Turchetto; Scialini Colombi; Massimo Bernardi; Jacopo Peccatori; Alessandra Pescarollo; Paolo Servida; Zulma Magnani; Serena K Perna; Veronica Valtolina; Fulvio Crippa; Luciano Callegaro; Elena Spoldi; Roberto Crocchiolo; Katharina Fleischhauer; Maurilio Ponzoni; Luca Vago; Silvano Rossini; Armando Santoro; Elisabetta Todisco; Jane Apperley; Eduardo Olavarria; Shimon Slavin; Eva M Weissinger; Arnold Ganser; Michael Stadler; Evangelia Yannaki; Athanasios Fassas; Achilles Anagnostopoulos; Marco Bregni; Corrado Gallo Stampino; Paolo Bruzzi; Claudio Bordignon
Journal:  Lancet Oncol       Date:  2009-04-01       Impact factor: 41.316

9.  A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.

Authors:  Stephan Mielke; Raquel Nunes; Katayoun Rezvani; Vicki S Fellowes; Annie Venne; Scott R Solomon; Yong Fan; Emma Gostick; David A Price; Christian Scotto; Elizabeth J Read; A John Barrett
Journal:  Blood       Date:  2007-09-18       Impact factor: 22.113

10.  Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide.

Authors:  Ashley Munchel; Chimen Kesserwan; Heather J Symons; Leo Luznik; Yvette L Kasamon; Richard J Jones; Ephraim J Fuchs
Journal:  Pediatr Rep       Date:  2011-06-22
  10 in total
  2 in total

Review 1.  T Cell-Depleted and T Cell-Replete HLA-Haploidentical Stem Cell Transplantation for Non-malignant Disorders.

Authors:  Alice Bertaina; Angela Pitisci; Matilde Sinibaldi; Mattia Algeri
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

Review 2.  γδ T Lymphocytes in the Diagnosis of Human T Cell Receptor Immunodeficiencies.

Authors:  Beatriz Garcillán; Ana V M Marin; Anaïs Jiménez-Reinoso; Alejandro C Briones; Miguel Muñoz-Ruiz; María J García-León; Juana Gil; Luis M Allende; Eduardo Martínez-Naves; María L Toribio; José R Regueiro
Journal:  Front Immunol       Date:  2015-01-29       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.